Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide in Pediatric Short Bowel Syndrome
NCT02682381Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of teduglutide in short bowel syndrome (SBS) (3 arms), sponsored by Takeda. Primary endpoint: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at 24 weeks. Started Jun 2016; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02682381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682381.